---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061525"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:17:23.630753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026

## Summary
- Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.
- Cash, equivalents, and marketable securities $215.4M as of Sept 30; funding operations into 2026.
- FDA cleared IND for TSC-203-A0201 targeting PRAME; plans to file two additional INDs by year-end.
- Expects initial heme program data at ASH Dec 2023; solid tumor Phase 1 enrollment by year-end 2023.
- R&D expenses $22.7M, up $7.7M YoY due to clinical start-up costs and personnel expansion.

## SEC filing metadata
- accession: 0000950170-23-061525
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/0000950170-23-061525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/tcrx-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061525
- JSON: https://secwatch.observer/filing/0000950170-23-061525.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.